Improvement of cardiac diastolic function by long-term centrally mediated sympathetic inhibition in one-kidney, one-clip hypertensive rabbits

American Journal of Hypertension

Volumn 21, Issue 1, 2008, Pages 54-60

  Signolet, Isabelle L ^a   Bousquet, Pascal P ^a   Monassier, Laurent J P ^a  

^a Laboratoire d'Anatomie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL; RILMENIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APPARATUS; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MODEL; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOPATHOLOGY; INOTROPISM; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RENOVASCULAR HYPERTENSION; SYMPATHETIC INNERVATION; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOMYOPATHIES; DIASTOLE; DISEASE MODELS, ANIMAL; HEART RATE; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; LIGATION; MALE; METOPROLOL; MYOCARDIAL CONTRACTION; NEPHRECTOMY; OXAZOLES; RABBITS; RENAL ARTERY; SYMPATHETIC NERVOUS SYSTEM; SYSTOLE; TIME FACTORS; VENTRICULAR FUNCTION; VENTRICULAR REMODELING;

EID: 38349168997     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2007.9     Document Type: Article

References (29)

1. Aeschbacher BC, Hutter D, Fuhrer J, Weidmann P, Delacretaz E, Allemann Y. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 2001; 14:106-113.
2. Schobel HP, Langenfeld M, Gatzka C, Schmieder RE. Treatment and post-treatment effects of α- versus β-receptor blockers on left ventricular structure and function in essential hypertension. Am Heart J 1996; 132:1004-1009.
3. Kobayashi M, Machida N, Mitsuishi M, Yamane Y. β-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens 2004; 17:1112-1119.
4. Nodari S, Metra M, Dei Cas L. β-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003; 5:621-627.
5. Gosse P, Roudaut R, Herrero G, Dallocchio M. β-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16(Suppl 5):S145-S150.
6. Thomas L, Gasser B, Bousquet P, Monassier L. Hemodynamic and cardiac anti-hypertrophic actions of clonidine in Goldblatt one-kidney, one-clip rats. J Cardiovasc Pharmacol 2003; 41:203-209.
7. Plehn JF, Foster E, Grice WN, Huntington-Coats M, Apstein CS. Echocardiographic assessment of LV mass in rabbits: models of pressure and volume overload hypertrophy. Am J Physiol 1993; 265:H2066-H2072.
8. Safar ME. Rilmenidine: a novel antihypertensive agent. Am J Med 1989; 87:24S-29S.
9. Lins RL, Daelemans R, Dratwa M, Verbeelen D, Sennesael J, Brisgand B, Lameire N. Acceptability of rilmenidine and long-term surveillance of plasma concentrations in hypertensive patients with renal insufficiency. Am J Med 1989; 87:41S-45S.
10. Akabane S, Natsume T, Matsushima Y, Deguchi F, Kuramochi M, Ito K. Alterations in renal Na+K+ATPase activity and [3H]ouabain binding in Goldblatt hypertensive rabbits. J Hypertens 1985; 3:469-474.
11. Sadowski Z, Szwed H, Kuch-Wocial A, Kubasik A, Januszewicz W, Krupa-Wojciechowska B, Polak G, Stejfa M, Dvorak I, Balazovjech I, Dubai G, Simon K. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study. J Hypertens Suppl 1998; 16:S55-S62.
12. Farsang C, Lengyel M, Borbas S, Zorandi A, Dienes BS. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin 2003; 19:205-217.
13. Koldas L, Ayan F, Ikitimur B. Short-term effects of rilmenidine on left ventricular hypertrophy and systolic and diastolic function in patients with essential hypertension: comparison with an angiotensin converting enzyme inhibitor and a calcium antagonist. Jpn Heart J 2003; 44:693-704.
14. Parkin ML, Godwin SJ, Head GA. Importance of imidazoline-preferring receptors in the cardiovascular actions of chronically administered moxonidine, rilmenidine and clonidine in conscious rabbits. J Hypertens 2003; 21:167-178.
15. Head GA, Burke SL, Chan CK. Site and receptors involved in the sympathoinhibitory actions of rilmenidine. J Hypertens Suppl 1998; 16:S7-S12.
16. Rauch AL, Campbell WG Jr. Synthesis of catecholamines in the hypothalamus and brainstem in one-kidney, one clip and two-kidney, one clip hypertension in rabbits. J Hypertens 1988; 6:537-541.
17. Slama M, Susic D, Varagic J, Frohlich ED. Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002;17:368-373.
18. Callens-el Amrani F, Paolaggi F, Swynghedauw B. Remodelling of the heart in DOCA-salt hypertensive rats by propranolol and by an α-2 agonist, rilmenidine. J Hypertens 1989; 7:947-954.
19. Zierhut W, Zimmer HG. Significance of myocardial α- and β-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res 1989; 65:1417-1425.
20. Phillips RA, Goldman ME, Ardeljan M, Arora R, Eison HB, Yu BY, Krakoff LR. Determinants of abnormal left ventricular filling in early hypertension. J Am Coll Cardiol 1989; 14:979-985.
21. Alli C, Di Tullio M, Mariotti G, Taioli E, Belli C, Radice M. Effects of long-term treatment with prazosin on left ventricular diastolic function in mild to moderate hypertension. Chest 1992; 101:181-186.
22. Agabiti-Rosei E, Muiesan ML, Rizzoni D, Zulli R, Calebich S, Beschi M, Castellano M, Muiesan G. Reduction of left ventricular hypertrophy after longterm antihypertensive treatment with doxazosin. J Hum Hypertens 1992; 6:9-15.
23. Hoffmann U, Globits S, Stefenelli T, Loewe C, Kostner K, Frank H. The effects of ACE inhibitor therapy on left ventricular myocardial mass and diastolic filling in previously untreated hypertensive patients: a cine MRI study. J Magn Reson Imaging 2001; 14:16-22.
24. Matsui H, Shimosawa T, Uetake Y, Wang H, Ogura S, Kaneko T, Liu J, Ando K, Fujita T. Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension 2006; 48:225-231.
25. Stefanadis C, Manolis A, Dernellis J, Tsioufis C, Tsiamis E, Gavras I, Gavras H, Toutouzas P. Acute effect of clonidine on left ventricular pressure-volume relation in hypertensive patients with diastolic heart dysfunction. J Hum Hypertens 2001; 15:635-642.
26. Frolov VA, Drozdova GA, Mustyatsa VF, Rieger P, Antoni Z, Kuzovkin AE. Possible mechanism of regression of myocardial hypertrophy. Bull Exp Biol Med 2001; 132:644-646.
27. Villars PS, Hamlin SK, Shaw AD, Kanusky JT. Role of diastole in left ventricular function, I: Biochemical and biomechanical events. Am J Crit Care 2004; 13:394-403; quiz 404-405.
28. Cimini CM, Gonzalez MA, Weiss HR. Reduction of cardiac hypertrophy in renal hypertensive rabbits with pindolol. J Pharmacol Exp Ther 1991; 257:541-546.
29. Dianzumba SB, DiPette D, Joyner CR, Cornman C, Townsend R, Mauro K, Weber E, Theobald T. Left ventricular filling in hypertensive blacks and whites following adrenergic blockade. Am J Hypertens 1990; 3:48-51.